AHK-Cu vs Ipamorelin
Well Studied vs Well Studied
synergistic Mechanism-based · 47% AHK-Cu and Ipamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
AHK-Cu Ipamorelin
Weight 416.9 Da 711.85 Da
Half-life Not established ~2 hours
Chain 3 amino acids 5 amino acids
Type Copper tripeptide complex Growth hormone secretagogue
Key Benefits
AHK-Cu
01 Hair follicle elongation stimulation
02 Dermal papilla cell proliferation
03 VEGF upregulation for improved scalp circulation
04 TGF-β1 reduction (counters DHT effects)
05 Anti-apoptotic protection for follicles
06 Collagen synthesis support
07 Convenient topical application
08 Fibroblast activation for skin regeneration
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Dosing Protocols
AHK-Cu
0.5-1% topical solution/serum / Once or twice daily application
Mesotherapy - Scalp (Practitioner) 0.1-0.5 mg per injection site Weekly sessions
Research Protocol 1-5 mg 2-3 times weekly
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Side Effects
AHK-Cu
Generally well-tolerated with excellent safety profile in topical applications
Rare scalp irritation (patch test recommended)
Potential for mild redness on sensitive skin
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Contraindications
Not for use on broken or infected skin
Avoid eye area - may cause irritation
Do not use if allergic to copper or peptides
Not recommended during acute skin infections
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Research Evidence
AHK-Cu Ipamorelin
Status Well Studied Well Studied
References 4 studies 5 studies
Latest March 2025 October 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.